Search

Your search keyword '"Elisabetta De Gasperi"' showing total 4 results
Start Over Author "Elisabetta De Gasperi"
4 results on '"Elisabetta De Gasperi"'

1. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

Author

Daphne D’Amato, Antonio De Vincentis, Federica Malinverno, Mauro Viganò, Domenico Alvaro, Maurizio Pompili, Antonino Picciotto, Valeria Pace Palitti, Maurizio Russello, Silvia Storato, Marie Graciella Pigozzi, Vincenza Calvaruso, Elisabetta De Gasperi, Ana Lleo, Antonino Castellaneta, Adriano Pellicelli, Nora Cazzagon, Annarosa Floreani, Luigi Muratori, Stefano Fagiuoli, Grazia Anna Niro, Valentina Feletti, Raffaele Cozzolongo, Natalia Terreni, Marco Marzioni, Rinaldo Pellicano, Pietro Pozzoni, Leonardo Baiocchi, Luchino Chessa, Floriano Rosina, Gaetano Bertino, Maria Vinci, Anna Morgando, Ester Vanni, Gaetano Scifo, Rodolfo Sacco, Maria D’Antò, Valentina Bellia, Roberto Boldizzoni, Silvia Casella, Barbara Omazzi, Guido Poggi, Laura Cristoferi, Alessio Gerussi, Vincenzo Ronca, Rosanna Venere, Francesca Ponziani, Maria Cannavò, Alessandro Mussetto, Rosanna Fontana, Francesco Losito, Evelise Frazzetto, Marco Distefano, Francesca Colapietro, Sara Labanca, Giulia Marconi, Giuseppe Grassi, Giovanni Galati, Sarah Elizabeth O’Donnell, Clara Mancuso, Giacomo Mulinacci, Andrea Palermo, Ernesto Claar, Antonio Izzi, Antonio Picardi, Pietro Invernizzi, Marco Carbone, and Umberto Vespasiani-Gentilucci

Subjects
Cholestasis, Cirrhosis, Overlap PBC-AIH, Autoimmunity, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background & aims: Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods: Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransferase (ALT) at 12 months. Safety and tolerability were also assessed. Results: We analysed 191 patients until at least 12 months of follow-up. Median age was 57 years, 94% female, 61 (32%) had cirrhosis, 28 (15%) had histologically proven overlap with autoimmune hepatitis (PBC-AIH). At 12 months, significant median reductions of ALP (-32.3%), ALT (-31.4%), and bilirubin (-11.2%) were observed. Response rates were 42.9% according to Poise criteria, and 11% by normal range criteria. Patients with cirrhosis had lower response than patients without cirrhosis (29.5% vs. 49.2%, p = 0.01), owing to a higher rate of OCA discontinuation (30% vs. 12%, p = 0.004), although with similar ALP reduction (29.4% vs. 34%, p = 0.53). Overlap PBC-AIH had a similar response to pure PBC (46.4% vs. 42.3%, p = 0.68), with higher ALT reduction at 6 months (-38% vs. -29%, p = 0.04). Thirty-three patients (17%) prematurely discontinued OCA because of adverse events, of whom 11 experienced serious adverse events. Treatment-induced pruritus was the leading cause of OCA discontinuation (67%). Conclusions: Effectiveness and safety of OCA under real-world conditions mirror those in the Poise trial. Patients with cirrhosis had lower tolerability. Overlap PBC-AIH showed higher ALT reduction at 6 months compared with patients with pure PBC. Lay summary: Obeticholic acid (OCA) was shown to be effective in more than one-third of patients not responding to ursodeoxycholic acid in a real-world context in Italy. Patients with cirrhosis had more side effects with OCA, and this led to suspension of the drug in one-third of patients. OCA was also effective in patients who had overlap between autoimmune hepatitis and primary biliary cholangitis.

Published
2021
Full Text
View/download PDF

2. Real-world experience with obeticholic acid in patients with primary biliary cholangitis

Author

Anna Morgando, Mauro Viganò, Ana Lleo, Maurizio Pompili, Elisabetta De Gasperi, Daphne D’Amato, Alessandro Mussetto, Nora Cazzagon, Pietro Invernizzi, Francesca Colapietro, Vincenzo Ronca, Sara Labanca, Ester Vanni, M.R. Cannavò, Francesco Losito, Ernesto Claar, G. Scifo, Giovanni Galati, Umberto Vespasiani-Gentilucci, Silvia Storato, Alessio Gerussi, Grazia Anna Niro, Antonio Izzi, Barbara Omazzi, Antonio De Vincentis, Valentina Feletti, Giuseppe Grassi, Valeria Pace Palitti, Clara Mancuso, Vincenza Calvaruso, Evelise Frazzetto, Roberto Boldizzoni, Marco Marzioni, Floriano Rosina, Andrea Palermo, Antonino Picciotto, Valentina Bellia, Gaetano Bertino, Italian Pbc Registry, Guido Poggi, Rodolfo Sacco, Domenico Alvaro, Luigi Muratori, Maria Vinci, Marie Graciella Pigozzi, Raffaele Cozzolongo, Natalia Terreni, Annarosa Floreani, Maurizio Russello, Marco Distefano, Rinaldo Pellicano, Maria D'Antò, Marco Carbone, Rosanna Venere, R. Fontana, Antonio Picardi, Silvia Casella, S. E. O'Donnell, Federica Malinverno, Stefano Fagiuoli, Laura Cristoferi, Luchino Chessa, Giacomo Mulinacci, Pietro Pozzoni, Antonino Castellaneta, Giulia Marconi, Adriano M. Pellicelli, Francesca Romana Ponziani, Leonardo Baiocchi, D'Amato, D, De Vincentis, A, Malinverno, F, Vigano, M, Alvaro, D, Pompili, M, Picciotto, A, Palitti, V, Russello, M, Storato, S, Pigozzi, M, Calvaruso, V, De Gasperi, E, Lleo, A, Castellaneta, A, Pellicelli, A, Cazzagon, N, Floreani, A, Muratori, L, Fagiuoli, S, Niro, G, Feletti, V, Cozzolongo, R, Terreni, N, Marzioni, M, Pellicano, R, Pozzoni, P, Baiocchi, L, Chessa, L, Rosina, F, Bertino, G, Vinci, M, Morgando, A, Vanni, E, Scifo, G, Sacco, R, D'Anto, M, Bellia, V, Boldizzoni, R, Casella, S, Omazzi, B, Poggi, G, Cristoferi, L, Gerussi, A, Ronca, V, Venere, R, Ponziani, F, Cannavo, M, Mussetto, A, Fontana, R, Losito, F, Frazzetto, E, Distefano, M, Colapietro, F, Labanca, S, Marconi, G, Grassi, G, Galati, G, O'Donnell, S, Mancuso, C, Mulinacci, G, Palermo, A, Claar, E, Izzi, A, Picardi, A, Invernizzi, P, Carbone, M, Vespasiani-Gentilucci, U, D'Amato D, De Vincentis A, Malinverno F, Viganò M, Alvaro D, Pompili M, Picciotto A, Palitti VP, Russello M, Storato S, Pigozzi MG, Calvaruso V, De Gasperi E, Lleo A, Castellaneta A, Pellicelli A, Cazzagon N, Floreani A, Muratori L, Fagiuoli S, Niro GA, Feletti V, Cozzolongo R, Terreni N, Marzioni M, Pellicano R, Pozzoni P, Baiocchi L, Chessa L, Rosina F, Bertino G, Vinci M, Morgando A, Vanni E, Scifo G, Sacco R, D'Antò M, Bellia V, Boldizzoni R, Casella S, Omazzi B, Poggi G, Cristoferi L, Gerussi A, Ronca V, Venere R, Ponziani F, Cannavò M, Mussetto A, Fontana R, Losito F, Frazzetto E, Distefano M, Colapietro F, Labanca S, Marconi G, Grassi G, Galati G, O'Donnell SE, Mancuso C, Mulinacci G, Palermo A, Claar E, Izzi A, Picardi A, Invernizzi P, Carbone M, Vespasiani-Gentilucci U, and Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group.

Subjects
upper limit of normal, Cirrhosis, ALT, AMA, Autoimmunity, antinuclear antibodies, ULN, PBC, Gastroenterology, UDCA, Settore MED/12, ULN, upper limit of normal, obeticholic acid, aRR, adjusted risk ratio, CRFs, case record form, AST, aspartate transferase, Clinical endpoint, GGT, gamma-glutamyl transferase, QC, primary biliary cholangitis, Ursodeoxycholic acid, ANA, TCC, Cholestasi, TIPS, Treatment Completer Cohort, ANA, antinuclear antibodie, medicine.medical_specialty, RR, UDCA, ursodeoxycholic acid, TIPS, transjugular intrahepatic portosystemic shunt, OCA, Cirrhosi, ALP, alkaline phosphatase, autoimmune hepatitis, medicine.disease, digestive system diseases, Discontinuation, Keywords: AIH, autoimmune hepatiti, QC, quality control, chemistry, gamma-glutamyl transferase, randomised controlled trial, electronic data capture, antimitochondrial antibodies, aspartate transferase, Autoimmune hepatitis, chemistry.chemical_compound, AIH, CRFs, Immunology and Allergy, adjusted risk ratio, ANA, antinuclear antibodies, RR, risk ratio, Overall cohort, ALT, alanine transferase, AMA, antimitochondrial antibodie, Cholestasis, CRFs, case record forms, Obeticholic acid, Overlap PBC-AIH, ursodeoxycholic acid, OCA, obeticholic acid, Tolerability, alkaline phosphatase, RCT, Research Article, medicine.drug, case record forms, Context (language use), AMA, antimitochondrial antibodies, Internal medicine, EDC, electronic data capture, transjugular intrahepatic portosystemic shunt, Internal Medicine, medicine, RCT, randomised controlled trial, OC, lcsh:RC799-869, quality control, alanine transferase, AST, aRR, Hepatology, business.industry, AIH, autoimmune hepatitis, TCC, Treatment Completer Cohort, PBC, primary biliary cholangiti, GGT, risk ratio, OC, Overall cohort, ALP, lcsh:Diseases of the digestive system. Gastroenterology, PBC, primary biliary cholangitis, business, EDC
Abstract

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransferase (ALT) at 12 months. Safety and tolerability were also assessed. Results We analysed 191 patients until at least 12 months of follow-up. Median age was 57 years, 94% female, 61 (32%) had cirrhosis, 28 (15%) had histologically proven overlap with autoimmune hepatitis (PBC-AIH). At 12 months, significant median reductions of ALP (-32.3%), ALT (-31.4%), and bilirubin (-11.2%) were observed. Response rates were 42.9% according to Poise criteria, and 11% by normal range criteria. Patients with cirrhosis had lower response than patients without cirrhosis (29.5% vs. 49.2%, p = 0.01), owing to a higher rate of OCA discontinuation (30% vs. 12%, p = 0.004), although with similar ALP reduction (29.4% vs. 34%, p = 0.53). Overlap PBC-AIH had a similar response to pure PBC (46.4% vs. 42.3%, p = 0.68), with higher ALT reduction at 6 months (-38% vs. -29%, p = 0.04). Thirty-three patients (17%) prematurely discontinued OCA because of adverse events, of whom 11 experienced serious adverse events. Treatment-induced pruritus was the leading cause of OCA discontinuation (67%). Conclusions Effectiveness and safety of OCA under real-world conditions mirror those in the Poise trial. Patients with cirrhosis had lower tolerability. Overlap PBC-AIH showed higher ALT reduction at 6 months compared with patients with pure PBC. Lay summary Obeticholic acid (OCA) was shown to be effective in more than one-third of patients not responding to ursodeoxycholic acid in a real-world context in Italy. Patients with cirrhosis had more side effects with OCA, and this led to suspension of the drug in one-third of patients. OCA was also effective in patients who had overlap between autoimmune hepatitis and primary biliary cholangitis., Graphical abstract, Highlights • Under real-world conditions, OCA was effective in ~43% of patients who were non-responders to UDCA, according to Poise criteria. • Patients with cirrhosis showed lower efficacy (29.5%), mainly attributed to reduced tolerability and higher discontinuation rate. • Patients with overlap AIH-PBC showed a comparable efficacy to pure PBC, with a higher ALT reduction at 6 months. • Most patients with PBC are still in need of additional therapy if aiming to normalise liver biochemistry.

Published
2021

3. AISF position paper on HCV in immunocompromised patients

Author

Gabriele Missale, Mauro Viganò, Marco Astegiano, Mauro Salizzoni, C. Chialà, Angelo Pera, Patrizia Racca, Massimo Di Maio, Mario Salomone, M. Puoti, Simone Parisi, Paolo Bironzo, M. Rendina, Carla Pasquina, Clodoveo Ferri, Luisa Pasulo, Rita Tozzi, A. Tucci, Pietro Lampertico, Emanuele Angelucci, Bruno Daniele, Patrizia Burra, Franco Riccardini, Marco Lagget, Fabio Salvatore Macaluso, Davide Giuseppe Ribaldone, Luca Miele, Clara Lisa Peroni, Raffaele Bruno, Anna Linda Zignego, Ambrogio Orlando, Giovanni Battista Gaeta, Giuseppe Montrucchio, Daniela Libertucci, Massimo Marignani, Agostino Colli, Enrico Fusaro, Antonio Craxì, Giorgio Maria Saracco, Barbara Imperatrice, Paolo Caraceni, Luisa Giaccone, Chiara Baratelli, Giuliano Torre, Luigi Biancone, Elisabetta De Gasperi, Mario Rizzetto, Maria Grazia Clemente, Francesco Paolo Russo, Aldo Giacardi, Riccardo Volpes, Edoardo G. Giannini, Daniele Curci, Rossella Della Valle, Salvatore Petta, Pierluigi Toniutto, Alessandro Busca, Pietro Vajro, Giorgio Verme, Chiara Mazzarelli, Paolo Grossi, Maria Chiara Ditto, Lorella Orsucci, Umberto Vitolo, Alberto Mella, Salvatore Madonia, Federica Cavallo, Maria Giuseppina Cabras, Stefano Bonora, Massimiliano Conforti, Vito Di Marco, Mario Pirisi, Giuseppe Cariti, Marta Coscia, Giuseppina Brancaccio, L. Scaglione, Stefano Fagiuoli, Alfredo Marzano, Stefano Cusinato, Roberto Minutolo, Giuseppe Rossi, Enrico Brignardello, Maurizia Rossana Brunetto, Marzano A., Angelucci E., Astegiano M., Baratelli C., Biancone L., Bironzo P., Brancaccio G., Brunetto M.R., Bruno R., Burra P., Cabras M.G., Caraceni P., Chiala C., Clemente M.G., Colli A., Daniele B., De Gasperi E., Di Marco V., Ditto M.C., Fagiuoli S., Ferri C., Gaeta G.B., Grossi P.A., Imperatrice B., Lampertico P., Macaluso F.S., Madonia S., Marignani M., Mazzarelli C., Mella A., Missale G., Parisi S., Pasulo L., Puoti M., Rendina M., Ribaldone D., Rossi G., Toniutto P., Tucci A., Vajro P., Vigano M., Volpes R., Zignego A.L., Giannini E.G., Miele L., Russo F.P., Petta S., Bonora S., Brignardello E., Busca A., Cariti G., Cavallo F., Conforti M., Coscia M., Craxi A., Curci D., Cusinato S., Di Maio M., Valle R.D., Fusaro E., Giacardi A., Giaccone L., Lagget M., Libertucci D., Minutolo R., Montrucchio G., Orlando A., Orsucci L., Pasquina C., Pera A., Peroni C.L., Pirisi M., Racca P., Riccardini F., Rizzetto M., Salizzoni M., Salomone M., Saracco G.M., Scaglione L., Torre G., Tozzi R., Vitolo U., Verme G., Angelucci, E, Astegiano, M, Baratelli, C, Biancone, L, Bironzo, P, Brancaccio, G, Brunetto, M, Bruno, R, Burra, P, Cabras, M, l Caraceni, P, Chialà, C, Clemente, M, Colli, A, Daniele, B, De Gasperi, E, Di Marco, V, Ditto, M, Fagiuoli, S, Ferri, C, Gaeta, G, Grossi, P, Imperatrice, B, Lampertico, P, Macaluso, F, Madonia, S, Marignani, M, Mazzarelli, C, Mella, A, Missale, G, Parisi, S, Pasulo, L, Puoti, M, Rendina, M, Ribaldone, D, Rossi, G, Toniutto, P, Tucci, A, Vajro, P, Viganò, M, Volpes, R, Zignego, A, Giannini, E, Miele, L, Russo, F, Petta, S, Bonora, S, Brignardello, E, Busca, A, Cariti, G, Cavallo, F, Conforti, M, Coscia, M, Craxì, A, Curci, D, Cusinato, S, Di Maio, M, Valle, R, Fusaro, E, Giacardi, A, Giaccone, L, Lagget, M, Libertucci, D, Minutolo, R, Montrucchio, G, Orlando, A, Orsucci, L, Pasquina, C, Pera, A, Peroni, C, Pirisi, M, Racca, P, Riccardini, F, Rizzetto, M, Salizzoni, M, Salomone, M, Saracco, G, Scaglione, L, Torre, G, Tozzi, R, Vitolo, U, Verme, G, Marzano, Alfredo, Angelucci, Emanuele, Astegiano, Marco, Baratelli, Chiara, Biancone, Luigi, Bironzo, Paolo, Brancaccio, Giuseppina, Brunetto, Maurizia Rossana, Bruno, Raffaele, Burra, Patrizia, Cabras, Maria Giuseppina, Caraceni, Paolo, Chialà, Claudia, Clemente, Maria Grazia, Colli, Agostino, Daniele, Bruno, De Gasperi, Elisabetta, Di Marco, Vito, Ditto, Maria Chiara, Fagiuoli, Stefano, Ferri, Clodoveo, Gaeta, Giovanni Battista, Grossi, Paolo Antonio, Imperatrice, Barbara, Lampertico, Pietro, Macaluso, Fabio Salvatore, Madonia, Salvatore, Marignani, Massimo, Mazzarelli, Chiara, Mella, Alberto, Missale, Gabriele, Parisi, Simone, Pasulo, Luisa, Puoti, Massimo, Rendina, Maria, Ribaldone, Davide, Rossi, Giuseppe, Toniutto, Pierluigi, Tucci, Alessandra, Vajro, Pietro, Viganò, Mauro, Volpes, Riccardo, Zignego, Anna Linda, Giannini, Edoardo G., Miele, Luca, Russo, Francesco Paolo, Petta, Salvatore, Bonora, Stefano, Brignardello, Enrico, Busca, Alessandro, Cariti, Giuseppe, Cavallo, Federica, Conforti, Massimiliano, Coscia, Marta, Craxì, Antonio, Curci, Daniele, Cusinato, Stefano, Di Maio, Massimo, Valle, Rossella Della, Fusaro, Enrico, Giacardi, Aldo, Giaccone, Luisa, Lagget, Marco, Libertucci, Daniela, Minutolo, Roberto, Montrucchio, Giuseppe, Orlando, Ambrogio, Orsucci, Lorella, Pasquina, Carla, Pera, Angelo, Peroni, Clara Lisa, Pirisi, Mario, Racca, Patrizia, Riccardini, Franco, Rizzetto, Mario, Salizzoni, Mauro, Salomone, Mario, Saracco, Giorgio Maria, Scaglione, Luca, Torre, Giuliano, Tozzi, Rita, Vitolo, Umberto, Verme, Giorgio, and Ditto, MARIA CHIARA

Subjects
medicine.medical_specialty, Transplant Recipient, Comorbidity, Antiviral Agents, Organ transplantation, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, Immunocompromised patient, Humans, Chronic, Intensive care medicine, Antiviral Agent, Hepatology, business.industry, Gastroenterology, Hepatitis C, Chronic, medicine.disease, Hepatitis C, Organ transplant, HCV, Immunocompromised patients, Transplant Recipients, Immunocompetence, Italy, 030220 oncology & carcinogenesis, HCV, Immunocompromised patients, Organ transplant, Position paper, Neoplasm, 030211 gastroenterology & hepatology, business, Direct acting, Human
Abstract

This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

Published
2018

4. Indolent B-Cell Lymphomas Treated Upfront with Antiviral Therapy: a Series of 13 Patients

Author

L. Cro, Alessio Aghemo, Michele Merli, Barbara Olivero, Daniele Vincenti, Francesca Gaia Rossi, Sara Rattotti, Luca Arcaini, Maria Goldaniga, Francesco Onida, A. Ferrario, Elisabetta De Gasperi, and Luca Baldini

Subjects
medicine.medical_specialty, business.industry, Anemia, Ribavirin, Immunology, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, Gastroenterology, Hematologic Response, Lymphoma, Surgery, chemistry.chemical_compound, B symptoms, chemistry, Median follow-up, Pegylated interferon, Internal medicine, Medicine, medicine.symptom, business, medicine.drug
Abstract

Abstract 2876 Background: HCV infection has been demonstrated to be involved in clonal B cell proliferation and in the subsequent development of non-Hodgkin's lymphoma (NHL). The regression of NHL after antiviral treatment is considered an indirect evidence of this pathogenetic relationship. Aim: to evaluate clinical course of patients affected by HCV infection (serology and HCV RNA positive) and low grade B-cell NHL (LG-NHL), not needing immediate treatment (absence of B symptoms, bulky disease or symptomatic tumor mass and lymphocyte doubling time less than 6 months) and treated upfront with antiviral therapy alone. Method: From 2006 to 2010, 13 patients, affected by LG- NHL at diagnosis have been treated with pegylated interferon (PegIFNa2a, 100–180 mcg weekly) and ribavirin (Rbv, 800–1200 mg daily) for a median treatment period of 6 months (6-18 months). Two patients are still in treatment. M/F ratio was 1.6 and median age was 59 years (range 51–73). The study included 9 marginal zone lymphomas (MZL: 2 splenic MZL, 7 extranodal non gastric MZL), 3 LG-NHL NOS and 1 lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia (LPL). Cryoglobulin were present in five patients. 7 pts had genotype 2, 5 pts genotype 1b, one not assessed; HCV infection was detected before lymphoma diagnosis in 9 pts and at lymphoma onset in 4 pts. Only 2 patients have previously received other combinations of antiviral therapy. Virologic response was assessed monthly by HCV-RNA polymerase chain reaction (PCR) and hematologic response was evaluated according to International Working Group response criteria (Cheson et al. J Clin Oncol. 2007) at the end of antiviral therapy. Results: Eleven patients completed the planned treatment course. Sustained virologic response (SVR) was achieved in 9 patients (6 with genotype 2); viremia clearance was achieved in a median period of 2 months (1-6). Among patients that gained a SVR, 5 achieved a complete response (CR) (3 genotype 2, 1 1b, one not assessed), one (genotype 2) partial response (PR), and 3 (2 genotype 2 and one genotype 1b) presented stable disease (SD). The remaining patients obtained only a reduction of viremia: one presented a SD and one was in PR. The treatment was well tolerated without any WHO grade III-IV toxicity. Among patients that completed treatment program, more frequent toxicity was haematological (one patient developed a WHO grade 1 anemia and one patients developed WHO grade 1 anemia and grade 2 neutropenia). After a median follow up of 17 months from the end of therapy (range 3–44), considering the 9 patients in SVR, only 2 (1 CR and 1 PR) progressed, maintaining SVR and one lost SVR maintaining SD. Patients that obtained only a reduction of viremia, maintained their hematologic status. Conclusion: We described a high CR rate in patients that obtained SVR after antiviral therapy (55%); the relationship between hematologic and viral response during follow up is not always stringent. We confirm that antiviral therapy could be considered as frontline therapeutic option in cases of HCV-related LG-NHL not requiring immediately immunochemotherapy. Disclosures: No relevant conflicts of interest to declare.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results